Released Feb 24, 2021, after the close
10-K filed Feb 24, 2021, 55 days after period end · 0001564590-21-008086
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.90M$15.90M derived+467.3% vs Q4 2019+110.3% vs Q3 2020
Net Income-$53.11M-$53.11M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$33,399,000N/M
Operating Cash Flowderived-$20,664,000N/M
Free Cash Flowderived-$22,936,000N/M
Margins · derived
Operating margin-210.1%+827.6 pt vs Q4 2019
Net margin-334.1%+675.9 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $15.90M | $2.80M | $1.66M | $1.03M |
| Net Income | -$53.11M | -$28.30M | -$16.03M | -$12.50M |
| EPS Diluted | — | -$0.37 | -$0.25 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR